amvuttra alnylam - Search News

FDA, Alnylam and American Heart Association

FDA approves new drug to treat protein buildup in the heart

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat protein

BioPharma Dive · 4d

Alnylam drug gets long-awaited FDA approval in deadly heart disease

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a fast-changing market.

Reuters on MSN · 4d

US FDA expands approval for Alnylam's drug to treat rare heart disease

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer's blockbuster Vyndaqel.

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Zacks Investment Research on MSN10h

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Alnylam Pharmaceuticals (ALNY) shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session.

Fierce Pharma4d

Alnylam's Amvuttra wins key approval in ATTR-CM, teeing up showdown with Pfizer

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results